Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Jefferies London Healthcare Conference 2021
25 slides from Sutro Biopharma's conference presentation, November 2021
Slide 1: Jefferies London Healthcare Conference
Jefferies London Healthcare Conference November 2021 Sutro Biopharma NASDAQ: STRO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Pioneer and Leader in Cell-Free Technology
Pioneer and Leader in Cell-Free Technology Optimizing cell-free platform for ADCs and beyond Additional value creation Multiple ADC through programs Building spinout showcasing ecosystem platform through breadth New strategic modalities and Establish partnerships extended cell-free value creation ec
Slide 4: Industry Leading Cell-Free Protein Synthesis Platform
Industry Leading Cell-Free Protein Synthesis Platform GMP production yields consistent and scalable end-products IgG with Non- Grow Cells Cellular Cell-Free Protein Natural Amino Linker-Warhead Homogenous from E. Coli Cell Lysis Extract Synthesis Acids Click Chemistry ADC 1 2 3 4 5 6 7 Specific to p
Slide 5: Advantages of Precision Protein Therapeutics
Advantages of Precision Protein Therapeutics Homogenous, precisely designed complex biologics with optimized performance Challenges in Traditional Cell-Based Complex Advantages of Sutro’s Cell-Free Synthesis Biologics Discovery and Manufacturing Platform for Best-in-Class Biologics Months to discove
Slide 6: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer
Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Bispecific Antibody Conjugated Antibody Cytokine Derivative ADC or ISAC iADC Prodrug Cytokine Modality Immune Cell Engager Bispecific ADC Derivative Tar
Slide 7: Cell-Free Platform Delivering Robust Pipeline
Cell-Free Platform Delivering Robust Pipeline Four product candidates in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Fast Track Designation STRO-002 FolRα ADC Endometrial NSCLC Lymphomas Antibody-Drug STRO
Slide 8: FolRα-Targeting ADC
STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 9: STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers
STRO 002 STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers FolRα targeting ADC with tubulin inhibitor cytotoxin potentially induces immunogenic cell death 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate- receptor alpha
Slide 10: STRO-002-GM1 Dose-Escalation Cohort Has Been Completed
STRO-002-GM1 Dose-Escalation Cohort Has Been Completed STRO 002 Heavily pre-treated ovarian cancer patients with six median line of prior therapies Part 1: Dose-Escalation Cohort in Ovarian All Patients Baseline Characteristic N=39 All-Comers STRO-002 6.4 mg/kg 61 years Ovarian Cancer Median age N=3
Slide 11: STRO-002 Was Generally Well Tolerated
STRO-002 Was Generally Well Tolerated STRO 002 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal Dose Levels in Dose-Escalation Common TEAEs > 25% By Grade (2) Overall All Patients All Safety Evaluable Grade 1 Grade 2 Grade 3 Grade 4 Dose Levels (Q3W) (N=39) (N=39) Patients N (%)
Slide 12: Tumor Reduction Observed in Majority of Patients
Tumor Reduction Observed in Majority of Patients STRO 002 10 patients met criteria for RECIST response including one CR Maximum Change (1) in Tumor Target Lesions (N=31) 20% RECIST- Objective Evaluable 0% Response per Population RECIST v1.1 (N=31) Responders 10 -30% Partial Response PRu PRu PRu CR (
Slide 13: Tumor Regression and Control Over Time
STRO 002 Tumor Regression and Control Over Time Deepening of responses and two patients with prolonged stable disease remaining on study Change in Sum of Diameters for Target Lesions Over Time (N=31) Change from baseline (%) 20 Best Overall Response (BOR) 0 PD SD PRu -30 PR CR Treatment ongoing as o
Slide 14: Clinical Benefit Seen in Heavily Pre-Treated Patient Population
Clinical Benefit Seen in Heavily Pre-Treated Patient Population STRO 002 Median duration of response is 5.8 months and three patients remained on study at over 18 months Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) CR Dose Level PR 2.9 mg/kg 3.5 mg/kg CR Individual patient
Slide 15: Favorable PFS Compared to Chemotherapy and Other Agents
Favorable PFS Compared to Chemotherapy and Other Agents STRO 002 Based on Kaplan-Meier estimates, median PFS was 7.2 months Durability at a Median Study Follow-up of 8.4 Months Endpoint Median 95% CI PFS (1) (N=39) 7.2 months (4.5 months, 10.8 months) DOR (2) (N=5) 5.8 months (2.0 months, not evalua
Slide 16: FolRα-Expression by Immunohistochemistry
FolRα-Expression by Immunohistochemistry STRO 002 Responses and anti-tumor activity observed across various FolRα-expression levels Immunohistochemistry Data (1) for Patients Treated at ≥ 2.9 mg/kg Individual Patients (N=18) (Ventana FOLR1 assay) 300 295 Best Overall 235 245 Response (BOR) 210 H-sco
Slide 17: Expanding the STRO-002 Franchise
STRO 002 Expanding the STRO-002 Franchise Enrollment completed in Dose-Expansion Cohort and new studies initiated Ovarian Cancer Dose-Escalation Cohort Dose-Expansion Cohort Combo Trial with Bevacizumab • 39 patients, 31 evaluable at active doses • > 40 patients enrolled in US and Spain • STRO-002 i
Slide 18: CD74-Targeting ADC
STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 19: Potential First-in-Class Molecule for Patients with NHL and MM
STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: 1 CD74 is expressed
Slide 20: STRO-001-BCM1 Study Design and Updates
STRO-001-BCM1 Study Design and Updates STRO 001 Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose-Escalation Study NHL Cohort Update at ASH 2020 R/R multiple myeloma Cohort A RP2D A total of 21 patients have been treated with (N=30) STRO-001 and 18 patients were ev
Slide 21: ASH 2020 Update in NHL Cohort
ASH 2020 Update in NHL Cohort STRO 001 Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) TEAEs by Grade, Patients With ≥1 Event, n (%) Age, median (range), years 64.5 (21–82) Occurring in ≥15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagno
Slide 22: Encouraging Interim Treatment Duration and Responses
Encouraging Interim Treatment Duration and Responses STRO 001 Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Dose Best Doses Duration of Demographics and Level, Prior Therapies PR Diagnosis Responses Received Treatment Individual pati
Slide 23: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources $254.2M Projected cash runway into in cash, cash equivalents & 2H 2023, marketable securities based on current business plans and as of Sept. 30, 2021 assumptions ~1.6M shares Funding received from our collaborators of of V
Slide 24: Driving Value Through Advancing Programs
Driving Value Through Advancing Programs Prioritizing expanding the STRO-002 franchise Program Indication Milestone / Achievement Timing Near final dose-escalation data ASCO 2021 Complete dose-expansion enrollment November 2021 Ovarian Cancer Initial dose-expansion data expected 2H 2021 STRO-002 EOP
Slide 25: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Arturo Molina, Ed Albini, MBA Chief Executive Officer and President of Research and MD, MS, FACP Chief Financial Officer Member of the Board of Chief Scientific Officer Chief Medical Officer Directors Jane Chung, RPh Shabbir Anik, PhD
Sutro Biopharma — Jefferies London Healthcare Conference 2021 on 6ix